DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al US 2002001 0208A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua et al. (43) Pub. Date: Jan. 24, 2002 (54) DHA-PHARMACEUTICAL AGENT Related U.S. Application Data CONJUGATES OF TAXANES (63) Continuation of application No. 09/135,291, filed on (76) Inventors: Victor Shashoua, Brookline, MA (US); Aug. 17, 1998, now abandoned, which is a continu Charles Swindell, Merion, PA (US); ation of application No. 08/651,312, filed on May 22, Nigel Webb, Bryn Mawr, PA (US); 1996, now Pat. No. 5,795,909. Matthews Bradley, Layton, PA (US) Publication Classification Correspondence Address: Edward R. Gates, Esq. (51) Int. Cl." ............................................ A61K 31/337 Wolf, Greenfield & Sacks, P.C. (52) U.S. Cl. .............................................................. 514/449 600 Atlantic Avenue Boston, MA 02210 (US) (57) ABSTRACT The invention provides conjugates of cis-docosahexaenoic (21) Appl. No.: 09/846,838 acid and pharmaceutical agents useful in treating noncentral nervous System conditions. Methods for Selectively target 22) Filled: Mayy 1, 2001 ingg pharmaceuticalp agents9. to desired tissues are pprovided. Patent Application Publication Jan. 24, 2002 Sheet 1 of 14 US 2002/0010208A1 1 OO 5 O -5OO - 1 OO-9 -8 -7 -6 -5 -4 LOG-10 OF SAMPLE CONCENTRATION (MOLAR) CCRF-CEM-o- SR ----- RPM-8226----- K-562- - -A - - HL-60 (TB) -g- - MOLT4: ... O Fig. 1 1 OO 5 O -5OO -1 O O -8 -7 -6 -5 -4 -- 9 LOGo OF SAMPLE CONCENTRATION (MOLAR) A549/ATCC-o-NS326. NCEKVX 28. --Q-- NCI-H322M-...-a---Eidsf8::... NC-H522--O-- HOP-62---Fig. 2 a-- NC-H460.-------- Patent Application Publication Jan. 24, 2002 Sheet 2 of 14 US 2002/0010208A1 COLON CANCER 1 OO - T - S. O 50 CD li O ()LL O - Z 5-501. -100-9 -8 -7 -6 -5 -4 LOGo OF SAMPLE CONCENTRATION (MOLAR) COLO 205-O- HCT-116--Q-- HCT-15- - -a- - - KM12- - e -- SW-62O---4--- HT29.....O...... Fig. 3 1 OO CNS CANCER 5 O -5OO -1 O O -8 -7 -6 -5 - 9 LOGo OF SAMPLE CONCENTRATION (MOLAR) SF-268-O-- SF-295 --K)-- SF-539 - - -A- - - SNB-75 -- 0 - - U251 - -e- - - SNB-19 . ] . Fig. 4 Patent Application Publication Jan. 24, 2002 Sheet 3 of 14 US 2002/0010208A1 MELANOMA 1 OO -8 -7 -6 -5 -4 LOGO OF SAMPLE CONCENTRATION (MOLAR) LOX IMV. -o- UACC-257- - - - SK-MEL-2- . O' SK-MEL-5 - - e - - M14 --- a-- MALME-3M--(- - Fig.UACC-62- 5 : A' -- 1 OO ARAN CANCE 5 O -5OO - 1 OO 9 -8 .7 -6 -5 -4 LOGo OF SAMPLE CONCENTRATION (MOLAR) GROW1 -O- OVCAR-3--O-- OVCAR-4--A- - OCWAR-8 - - - - SK-OV-3 - - - - - OVCAR-5 ro-r Fig. 6 Patent Application Publication Jan. 24, 2002. Sheet 4 of 14 US 2002/0010208A1 OO 5 O O -9 LOG10 OF SAMPLE CONCENTRATION (MOLAR) 786-O-O- A498- -g- - ACHN- - -A- - - CAK-1: ... RX 393-- e - - K-10---0--- UO-31 - - -A- Fig. 7 1 OO PROSTRATE CANCER O O LOGo OF SAMPLE CONCENTRATION (MOLAR) PC-3-O- Fig. 8 Patent Application Publication Jan. 24, 2002 Sheet 5 of 14 US 2002/0010208A1 1 OO BREAST CANCER 5 O -5 OO -100 -8 -7 -6 -5 -4 LOGo OF SAMPLE CONCENTRATION (MOLAR) MCF7 -O- MDA-N- - - - - - HS 578...-O.... MDA-MB-435 - -e- - MDA-MB-231/ - - A - - T-47D-...-a-...- MCF 7ADR-RE-i-o- Fig.BT-549-a- 9 1 OO LEUKEMA 5 O -5 OO -1 OO -9 -8 -7 -6 -5 -4 CCRF-CEM--o-LOGo OF SAMPLE CONCENTRATIONSR- - - - - - (MOLAR) RPM-8226--e--- K-562 - - -A - - HL-60 (TB) -g- -Fig. MOLT-4 10 to . Patent Application Publication Jan. 24, 2002 Sheet 6 of 14 US 2002/0010208A1 1 OO 5 O -5OO -100-9 -8 -7 -6 -5 -4 LOGo OF SAMPLE CONCENTRATION (MOLAR) A549/ATCC-O- EKVX --Q-- NCI-H322M----a--- NCI-H226-- - - NC-H23----- HOP-92.......... NC-H522--O-- HOP-62----Fig. 11 NC-H460-a--- 1 OO 5 O O -5 -100 9 -8 -7 -6 -5 -4 LOGO OF SAMPLE CONCENTRATION (MOLAR) COLO 205-O- HCT-116--Q-- HCT-15---a--- KM12-- e - -Fig. SW-620 12 - - - - - - HT29. Patent Application Publication Jan. 24, 2002 Sheet 7 of 14 US 2002/0010208A1 1 OO 5 O -5OO -1 O O-9 -8 -7 -6 -5 -4 LOGo OF SAMPLE CONCENTRATION (MOLAR) SF-268-O- SF-295 --K)-- SF-539 - - - A - - - SNB-75 -- 9 - - Fig.251 - 139 - SNB-19-0- 1 OO 5 O -5OO - 1 O O 9 -8 -7 -6 - -4 LOG-10 OF SAMPLE CONCENTRATION (MOLAR) LOX IMV. --O- UACC-257- --- SK-MEL-2..... 0-..... SK-MEL-5 - -e-- M14 --- a-- MALME-3M--Q- - UACC-62 - - - -a - Fig. 14 Patent Application Publication Jan. 24, 2002. Sheet 8 of 14 US 2002/0010208A1 OVARAN CANCER 1 OO Cys's S. 5 O -5 OO - 100 a -9 -8 -7 -6 -5 -4 LOGo OF SAMPLE CONCENTRATION (MOLAR) GROW 1 -O- OVCAR-3--K) -- OWCAR-4--A- - OCVAR-8 - - - - SK-OV3Fig. - - - 15 - - OVCAR-5 “d OO RENAL CANCEF 5 O -5 OO -1 O O -9 -8 -7 -6 -5 -, LOGo OF SAMPLE CONCENTRATION (MOLAR) 786-O-O-, - A498--K) - ACHN- - -A--- CAK-1: . RXF 393-- 9 - - TK-10---0-- UO-31 - A - Fig. 16 Patent Application Publication Jan. 24, 2002 Sheet 9 of 14 US 2002/0010208A1 1 OO PROSTRATE CANCER -- O - 1 OO -9 -8 -7 -6 -5 -4 LOGo OF SAMPLE CONCENTRATION (MOLAR) PC-3-O Fig. 17 1 OO 5 O -5 OO -100 -8 -7 -6 -5 -4 LOG10 OF SAMPLE CONCENTRATION (MOLAR) MCF 7 -O- MDA-N- -0-- HS 578T....... MDA-MB-435- -o- - MDA-MB-231/ --A-- T-47D-...- MCF 7/AOR-RE--K)-- BT-549 -...-A-...- Fig. 18 Patent Application Publication Jan. 24, 2002. Sheet 10 of 14 US 2002/0010208A1 EUKEMA 1 O -9 -8 -7 -6 LOGo OF SAMPLE CONCENTRATION (MOLAR) CCRF-CEM-O- MOLT-4---A- - - K-562 - (- - Fig.f SR 19 . .O. NON-SMALL CELL LUNG CANCER C - - -- -6 LOGo OF SAMPLE CONCENTRATION (MOLAR) A549/ATCC-o-, NC.-H.322M-...-0.-. NC-H226 .......O...... NC-H23---- HOP-62 --- a--- NC-H522 - - -si-...- EKWX-- C -- NC-H46O -- a--- Fig. 20 Patent Application Publication Jan. 24, 2002 Sheet 11 of 14 US 2002/0010208A1 COLON CANCER l H S. O 1. CD 1 O l CD H l O 1. I - O -9 -8 -7 -6 LOGO OF SAMPLE CONCENTRATION (MOLAR) COLOHT29- 205-O- - - - city'sKM12---0--- HCT-15 soro so e - ea as a HCC-2995- - C)-- SW-620-...--A-...-Fig. 21 CNS CANCER 1 OO - - - - - H s O 1. CD l O 9- 2. il O 1. L Cl - 1 OO- 1 O -9 -8 -7 -6 LOGo OF SAMPLE CONCENTRATION (MOLAR) SF-268-O-- SF-295 - -g- - SF-539 - - - a- - - SNB-75 -- 0 - - U251 - '-8- - - SNB-19.- ... O. Fig. 22 Patent Application Publication Jan. 24, 2002 Sheet 12 of 14 US 2002/0010208A1 MELANOMA 1 O -9 -8 -7 -6 LOGO OF SAMPLE CONCENTRATION (MOLAR) LOX MV -o- SK-MEL-5- - - - SK-MEL-2. --O-.... SK-MEL-28 - () - M14 --- a-- UACC-62 -...-a- " - MALME-3M--Q-- Fig.UACC-257- 23 - - A - OWARIAN CANCER LOGO OF SAMPLE CONCENTRATION (MOLAR) IGROV1 -o- OVCAR-3--O--OVCAR-4--a-- OCVAR-8 - - - - SK-OV-3-...-0.-Fig. 24 : OWCAR-5"O" Patent Application Publication Jan. 24, 2002 Sheet 13 of 14 US 2002/0010208A1 Her S. O 1. CD L O L CD CC - 2. 5-50Y - 1 OO- 10 -9 -8 .7 -6 LOGO OF SAMPLE CONCENTRATION (MOLAR) 786-O-O- . A498--KX- - ACHN- - - A - - - CAK-1: .... O RXF 393 - - 3 - - SN12CFig. -- (- - - 25 TK-1 O - A - UO-31 - ... a PROSTRATE CANCER o -9 -8 -7 -6 LOGo OF SAMPLE CONCENTRATION (MOLAR) PC-3-O- DU-145-Fig. -O-- 26 Patent Application Publication Jan. 24, 2002 Sheet 14 of 14 US 2002/0010208A1 BREAS CANCER E S. O 1. CD ll O CD 2. O 1. l - O g - -7 -6 LOG10 OF SAMPLE CONCENTRATION (MOLAR) MCF 7 -O- MDA-N---4--. - HS 578T. O.... MDA-MB-435- -e- - MDA-MB-231/ -- a-- -47D---a-...- MCF 71ADR-RE--&- B-549-...-A-...- Fig. 27 US 2002/0010208A1 Jan. 24, 2002 DHA-PHARMACEUTICAL AGENT CONJUGATES 0006 Taxol has the following formula: OF TAXANES BACKGROUND OF THE INVENTION AcO O OH 0001 Improving drug selectivity for target tissue is an established goal in the medical arts. In general, it is desirable H O to deliver a drug Selectively to its target, So that dosage and, X. consequently, Side effects can be reduced. This is particu Y Yo Y Y Ph 3 2 O i larly the case for toxic agents Such as anti-cancer agents HO because achieving therapeutic doses effective for treating the H PhCO2 A.C cancer is often limited by the toxic side effects of the anti-cancer agent on normal, healthy tissue. The problems relating to lack of drug Selectivity can be exemplified by 0007 Taxanes have the basic three ring structure (A. B TaxolcE). and C), Substituted or unsubstituted. 0002 Taxole (paclitaxel) was first isolated in 1971 from 0008 Taxol's carbons are numbered conventionally as the bark of Taxus brevifolia and was approved in 1992 by the follows: US Food and Drug Administration for treatment of meta Static Ovarian cancer and later for breast cancer. Its mecha nism of action is believed to involve promoting formation and hyperStabilization of microtubules, thereby preventing the disassembly of microtubules necessary for completion of cell division. It also has been reported that Taxol induces expression of cytokines, affects the activity of kinases and blockS processes essential for metastasis, in as yet unchar acterized mechanisms of action.
Load more

Recommended publications
  • List of Covered Drugs
    List of Covered Drugs Effective July 1, 2016 INTRODUCTION We are pleased to provide the 2011 Gold Coast Health Plan List of Covered Drugs as a useful reference and informational tool. The GCHP List of Covered Drugs can assist practitioners in selecting clinically appropriate and cost effective products for their patients. The information contained in the GCHP List of Covered Drugs is provided solely for the convenience of medical providers. We do not warrant or assure accuracy of such information nor is it intended to be comprehensive in nature. This List of Covered Drugs is not intended to be a substitute for the knowledge, expertise, skill and judgment of the medical provider in his or her choice of prescription drugs. All the information in this List of Covered Drugs is provided as a reference for drug therapy selection. Specific drug selection for an individual patient rests solely with the prescriber. We assume no responsibility for the actions or omissions of any medical provider based upon reliance, in whole or in part, on the information contained herein. The medical provider should consult the drug manufacturer's product literature or standard references for more detailed information. National guidelines can be found on the National Guideline Clearinghouse site at http://www.guideline.gov PREFACE The GCHP List of Covered Drugs is organized by sections. Each section is divided by therapeutic drug class primarily defined by mechanism of action. Unless exceptions are noted, generally all applicable dosage forms and strengths of the drug cited are included in the GCHP List of Covered Drugs. Generics should be considered the first line of prescribing.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Drug Antioxidant Effects a Basis for Drug Selection?
    REVIEW ARTI LE Drugs 42 (4): 569-605, 1991 00 12-6667/ 91/ 00 I0-0569/ $ 18.50/0 © Adis International Limited. All rights reserved. DRU161 Drug Antioxidant Effects A Basis for Drug Selection? Barry Halliwell Pulmonary Medicine, UC Davis Medical Center, Sacramento , California, USA Contents 570 Summary 570 I. What is a Free Radical? 570 1.1 Definition of a Free Radical 57/ 1.2 Hydroxyl Radical 572 1.3 Formation of Oxygen Radicals In Vivo 574 1.4 Reactive Oxygen Species 575 1.5 Transition Metal Ions and Free Radical Reactions 575 1.6 Antioxidant Defence In Vivo: Intracellular 576 1.7 Antioxidant Defence In Vivo: Extracellular 579 2. Free Radical Damage to Cells and the Protective Ability of Antioxidants 579 2.1 Mechanisms of Cell Damage: The Molecular Targets 58/ 2.2 How to Characterise an Antioxidant 5 2 3. The Role of Free Radicals in Human Disease 582 3.1 Causation of Disease 582 3.2 A Significant Consequence of Disease Pathology 584 3.3 A General Consequence of Tissue Injury 585 3.4 What Can We Expect from Antioxidant Therapy? 586 586 4. Antioxidants in Disease Therapy 586 4.1 Use of Naturally Occurring Antioxidants and Derived Compounds 587 4.1.1 Superoxide Dismutase 587 4.1.2 Superoxide Dismutase 'Mimics' 588 4.1.3 a-Tocopherol 589 4.1.4 Ascorbic Acid (Vitamin C) 589 4.1.5 Adenosine 589 4.1.6 Lactoferrin 590 4.1.7 Nicotinamide 59/ 4.1.8 Glutathione and its Precursors 59/ 4.1.9 Carotenoids 59/ 4.2 'Synthetic' Antioxidants 59/ 4.2.1 Mercaptopropionylglycine and Other Thiols 592 4.2.2 Ebselen: A Glutathione Peroxidase Mimic? 593 4.2.3 Allopurinol, Oxypurinol and Other Xanth ine Oxidase Inhibitors 593 4.2.4 Inhibitors of the Generation of Reactive Oxygen Species by Phagocytes 595 4.2.5 Chelating Agents: Deferoxamine 595 4.2.6 Other Iron Chelators: Hydroxypyridones 596 4.2.7 Other Iron Chelators: ICRF-187 and the 'Lazaroids' 4.2.8 Probucol and Other Chain-Breaking Antioxidants 570 Drugs 42 (4) 1991 596 5.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Review Article
    Free Radical Biology & Medicine, Vol. 33, No. 6, pp. 774–797, 2002 Copyright © 2002 Elsevier Science Inc. Printed in the USA. All rights reserved 0891-5849/02/$–see front matter PII S0891-5849(02)00956-5 Review Article STRUCTURE AND FUNCTION OF XANTHINE OXIDOREDUCTASE: WHERE ARE WE NOW? ROGER HARRISON Department of Biology and Biochemistry, University of Bath, Bath, UK (Received 11 February 2002; Accepted 16 May 2002) Abstract—Xanthine oxidoreductase (XOR) is a complex molybdoflavoenzyme, present in milk and many other tissues, which has been studied for over 100 years. While it is generally recognized as a key enzyme in purine catabolism, its structural complexity and specialized tissue distribution suggest other functions that have never been fully identified. The publication, just over 20 years ago, of a hypothesis implicating XOR in ischemia-reperfusion injury focused research attention on the enzyme and its ability to generate reactive oxygen species (ROS). Since that time a great deal more information has been obtained concerning the tissue distribution, structure, and enzymology of XOR, particularly the human enzyme. XOR is subject to both pre- and post-translational control by a range of mechanisms in response to hormones, cytokines, and oxygen tension. Of special interest has been the finding that XOR can catalyze the reduction of nitrates and nitrites to nitric oxide (NO), acting as a source of both NO and peroxynitrite. The concept of a widely distributed and highly regulated enzyme capable of generating both ROS and NO is intriguing in both physiological and pathological contexts. The details of these recent findings, their pathophysiological implications, and the requirements for future research are addressed in this review.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Medical Policy Statement
    MEDICAL POLICY STATEMENT Effective Next Annual Last Review / Date Review Date Revision Date 06/15/2011 06/15/2012 06/15/2011 Author Shelley Jones RN, CCM, Wendy Null RPh CSMG Medical Policy Statements are derived from literature based and supported clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services are those health care services or supplies which are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative and are not provided mainly for the convenience of the member or provider. A. SUBJECT Alglucerase (Ceredase) Infusion B. BACKGROUND Alglucerase (Ceredase) is a modified form of the enzyme, ß-glucocerebrosidase (ß-D- glucosyl-N-acylsphingosine glucohydrolase). Alglucerase (Ceredase) catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids. Glucocerebroside is primarily derived from hematologic cell turnover. Gaucher disease is characterized by a functional deficiency in ß-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages, which become engorged and are termed Gaucher cells. The patient selection criteria outlined was derived from the FDA-approved prescribing information for alglucerase (Ceredase), the studies that were presented to the FDA in support of the pre-market approval application, and studies in the peer-reviewed published medical literature.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]